MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axim Biotechnologies Inc (OP:AXIM)

0.0131 UNCHANGED
Streaming Delayed Price Updated: 2:26 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0131
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0131
Today's Range 0.0131 - 0.0131
52wk Range 0.0026 - 0.0288
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Via NewMediaWire
Topics Cannabis Intellectual Property
Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Via NewMediaWire
Topics Cannabis Intellectual Property

Performance

YTD
+13.9%
+13.9%
1 Month
+22.4%
+22.4%
3 Month
+35.1%
+35.1%
6 Month
+142.6%
+142.6%
1 Year
+244.7%
+244.7%

More News

Read More
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Via TheNewswire.com
Topics Cannabis Intellectual Property
Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Via TheNewswire.com
Topics Cannabis Intellectual Property
News headline image
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
Via NewMediaWire
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
Via TheNewswire.com
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
Via TheNewswire.com
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
Via TheNewswire.com
News headline image
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
Via NewMediaWire
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
Via TheNewswire.com
News headline image
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
Via NewMediaWire
News headline image
Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
Via NewMediaWire
News headline image
AXIM Biotechnologies Receives Medical Device Manufacturing License
Via NewMediaWire
News headline image
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
Via NewMediaWire
News headline image
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
Via NewMediaWire
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
Via TheNewswire.com
AXIM Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
Via NewMediaWire
News headline image
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
From AXIM Biotechnologies, Inc.
Via Business Wire
News headline image
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
From AXIM Biotechnologies, Inc.
Via Business Wire
News headline image
Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Via NewMediaWire
News headline image
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Via NewMediaWire
News headline image
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
Via NewMediaWire
News headline image
AXIM Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
Via NewMediaWire
News headline image
AXIM Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
Via NewMediaWire
News headline image
AXIM Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
Via NewMediaWire
Topics Intellectual Property

Frequently Asked Questions

Is Axim Biotechnologies Inc publicly traded?
Yes, Axim Biotechnologies Inc is publicly traded.
What exchange does Axim Biotechnologies Inc trade on?
Axim Biotechnologies Inc trades on the OTC Traded
What is the ticker symbol for Axim Biotechnologies Inc?
The ticker symbol for Axim Biotechnologies Inc is AXIM on the OTC Traded
What is the current price of Axim Biotechnologies Inc?
The current price of Axim Biotechnologies Inc is 0.0131
When was Axim Biotechnologies Inc last traded?
The last trade of Axim Biotechnologies Inc was at 02/04/26 02:26 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story